Corbus Pharmaceuticals Stock Price - CRBP

7.62
-0.39 (-4.87%)
Upgrade to Real-Time
Regular Market
7.62
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Corbus Pharmaceuticals Holdings Inc CRBP NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.39 -4.87% 7.62 7.31 8.19 8.11 8.01 11:50:46
Bid Price Ask Price Spread Spread % News
7.62 7.64 0.02 0.26% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,562 714,493 $ 7.69 $ 5,494,978 938,967 3.29 - 8.66
Last Trade Time Type Quantity Stock Price Currency
11:50:47 100 $ 7.62 USD

Corbus Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 555.75M 72.49M 69.25M $ 36.14M $ - -1.13 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Corbus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRBP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week7.258.667.147.871,459,7780.375.1%
1 Month6.328.665.757.001,036,8801.3020.57%
3 Months4.898.663.295.63985,8752.7355.83%
6 Months4.568.663.295.73907,0493.0667.11%
1 Year7.358.663.295.72765,6680.273.67%
3 Years6.409.9553.296.61852,4951.2219.06%
5 Years3.8010.781.016.44776,4983.82100.53%

Corbus Pharmaceuticals Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.


Your Recent History
NASDAQ
CRBP
Corbus Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.